SubsidieMeestersIMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
Projectdetails
Introduction
The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need.
Project Overview
The project REGENERAR aims to develop a non-viral delivery formulation up to TRL4 for the delivery of an epigenetic reprogramming formulation to reprogram glial cells into neurons.
In Vitro Testing
The in vitro safety and targeting of the formulation will be tested against:
- Glial cells
- Organotypic cortical slice cultures
Several routes of administration will be tested to enhance the accumulation of the formulation in the brain.
In Vivo Evaluation
In addition, the in vivo safety, elimination, targeting, and epigenetic reprogramming will be evaluated.
Toxicological Studies
Toxicological studies will be performed in GLP conditions to evaluate both in vivo systemic and local (brain) effects of the formulation.
Stakeholder Involvement
The development of the non-viral formulation will take into account the contributions of key stakeholders in the area of gene editing, health institutions, patient associations, among others.
Roadmap Development
A roadmap will be developed for upscaling innovation to higher TRLs upon the end of the action.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.943.233 |
| Totale projectbegroting | € 2.943.233 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 29-2-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSIDADE DE COIMBRApenvoerder
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
- SOCIEDADE PORTUGUESA DE INOVACAO CONSULTADORIA EMPRESARIAL E FOMENTO DA INOVACAO SA
- FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
- Single Technologies AB
- HOVIONE FARMACIENCIA SA
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation. | EIC Pathfinder | € 2.996.550 | 2022 | Details |
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images. | EIC Pathfinder | € 2.744.300 | 2022 | Details |
Dynamic Spatio-Temporal Modulation of Light by Phononic ArchitecturesDynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements. | EIC Pathfinder | € 2.552.277 | 2022 | Details |
Emerging technologies for crystal-based gamma-ray light sourcesTECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology. | EIC Pathfinder | € 2.643.187 | 2022 | Details |
"Creation of innovative ""humidity to electricity"" renewable energy conversion technology towards sustainable energy challenge"
The CATCHER project aims to develop scalable technology for converting atmospheric humidity into renewable electricity, enhancing EU leadership in clean energy innovation.
Quantitative Ultrasound Stochastic Tomography - Revolutionizing breast cancer diagnosis and screening with supercomputing-based radiation-free imaging.
The project aims to revolutionize breast cancer imaging by developing adjoint-based algorithms for uncertainty quantification, enhancing diagnostic confidence through high-resolution, radiation-free images.
Dynamic Spatio-Temporal Modulation of Light by Phononic Architectures
Dynamo aims to revolutionize imaging technologies by enabling simultaneous light modulation at GHz rates, enhancing processing speed and positioning Europe as a leader in optical advancements.
Emerging technologies for crystal-based gamma-ray light sources
TECHNO-CLS aims to develop novel gamma-ray light sources using oriented crystals and high-energy particle beams, enhancing applications in various scientific fields through innovative technology.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC COG | € 2.249.895 | 2022 | Details |
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic DiseasesDevelop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment. | ERC ADG | € 2.495.250 | 2022 | Details |
Rewiring gene regulatory circuits to enhance central nervous system repairThis project aims to rewire gene expression in mammalian neural stem cells using synthetic enhancers to promote regeneration after CNS injury, enhancing cell replacement and gene therapy strategies. | ERC STG | € 1.500.000 | 2023 | Details |
Microglia engineering and replacement to treat brain diseaseThe ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies. | ERC COG | € 2.000.000 | 2023 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases
Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.
Rewiring gene regulatory circuits to enhance central nervous system repair
This project aims to rewire gene expression in mammalian neural stem cells using synthetic enhancers to promote regeneration after CNS injury, enhancing cell replacement and gene therapy strategies.
Microglia engineering and replacement to treat brain disease
The ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies.